What is the current Price Target for the Viking Therapeutics, Inc. stock?

The average Viking Therapeutics, Inc. target price is $90.26. This is 217.49% higher than the current stock price. The highest price target is 339.68%, the lowest is 5.52%. 19 Analysts have issued a price target Viking Therapeutics, Inc. 2026 .

How high will the Viking Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Viking Therapeutics, Inc. stock will rise. The performance of stocks, including the Viking Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Viking Therapeutics, Inc. stock today?

The performance of Viking Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Viking Therapeutics, Inc. stock fall?

The decline in Viking Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Viking Therapeutics, Inc. Forecast, price target & analysts

$28.43

3.76% day before yesterday

Nasdaq, May 16, 10:14 pm CET

ISIN

US92686J1060

Symbol

VKTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Viking Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Viking Therapeutics, Inc. Classifications & Recommendation:

Buy

89%

Hold

11%

Viking Therapeutics, Inc. Price Target

Target Price	$90.26
Price	$28.43
Potential	217.49% register free of charge
Number of Estimates	19

	19 Analysts have issued a price target Viking Therapeutics, Inc. 2026 . The average Viking Therapeutics, Inc. target price is $90.26. This is 217.49% register free of charge higher than the current stock price. The highest price target is $125.00 339.68% register free of charge , the lowest is $30.00 5.52% register free of charge .
	A rating was issued by 19 analysts: 17 Analysts recommend Viking Therapeutics, Inc. to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Viking Therapeutics, Inc. stock has an average upside potential 2026 of 217.49% register free of charge . Most analysts recommend the Viking Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.01	-1.88
	10.99%	86.14%
P/E		negative
EV/Sales		1,592.64

19 Analysts have issued a Viking Therapeutics, Inc. forecast for earnings per share. The average Viking Therapeutics, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.01	10.99%
2025	$-1.88 86.14% Unlock
2026	$-2.56 36.17% Unlock
2027	$-2.97 16.02% Unlock
2028	$-2.77 6.73% Unlock
2029	$-0.59 78.70% Unlock

Current	-24.69	68.82%
2025	-15.10 38.84% Unlock
2026	-11.11 26.42% Unlock
2027	-9.57 13.86% Unlock
2028	-10.25 7.11% Unlock
2029	-48.07 368.98% Unlock

Viking Therapeutics, Inc....

Current Viking Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Truist Securities	Locked ➜ Locked	Locked	Apr 28 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	Apr 28 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 24 2025
Morgan Stanley	Locked ➜ Locked	Locked	Apr 24 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 17 2025
Goldman Sachs	Locked ➜ Locked	Locked	Apr 08 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 26 2025

Analyst Rating	Date
Locked Truist Securities: Locked ➜ Locked	Apr 28 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	Apr 28 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 24 2025
Locked Morgan Stanley: Locked ➜ Locked	Apr 24 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 17 2025
Locked Goldman Sachs: Locked ➜ Locked	Apr 08 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 26 2025

Discover more stocks with a high price target

TUI 57.08%

Novo Nordisk 53.62%

BioNTech SE - ADR 44.95%

MongoDB 36.70%

NIO ADR 30.21%

Alibaba Group Holding Ltd 28.29%

Pfizer 23.80%

Tencent Holdings Ltd. 21.83%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now